The New Bioethics

期刊简介：The New Bioethics seeks to reclaim bioethics as a diverse and multidisciplinary project. It provides a space for dialogue between different perspectives on biotechnology and the human body and offers the chance to find new kinds of common ground. The journal invites contributions from a range of perspectives, from STEAM, law, philosophy, social and political sciences and theology from diverse religions. The journal, whilst regularly publishing papers on longstanding ethical issues such as brain death and conscientious objection in healthcare, focuses on the interface of new advances and the human body. It covers such issues as genomic editing, regenerative medicine (including the use of stem cells), human enhancement, ectogenesis and animal-human hybrids. In addition to research papers and book reviews, The New Bioethics has an Essay section which allows authors the opportunity to explore an issue in greater depth than in papers which are limited to 7000 words. Inquiries about the suitability of papers or to discuss potential topics for the Essay section or special issues can be made to matthew.james@stmarys.ac.uk . Peer Review Policy Submitted papers deemed to be appropriate for peer review by the Editor-in-Chief will be subjected to rigorous anonymous review by independent referees under the supervision of the Editor-in-Chief and the Managing Editor, with the help of a distinguished international advisory board . The Journal operates a double-anonymized peer review system, with a minimum of two reviews per paper. Submissions can be made through the online submission system www.edmgr.com/nbi Publishing Ethics The Journal adheres to the highest standards of publishing ethics, with rigorous processes in place to ensure this is achieved. Taylor & Francis is a member of Committee of Publications Ethics (COPE) and utilises CrossCheck for all Journals. More information on our ethical standards and policies can be found here: http://authorservices.taylorandfrancis.com/ethics-for-authors/ The Journal has an appeals and complaints policy which can be viewed here: https://authorservices.taylorandfrancis.com/peer-review-appeals-and-complaints-from-authors/ .

【译文】新生物伦理学试图将生物伦理学重新塑造为一个多元化、多学科的项目。它为生物技术和人体的不同观点之间的对话提供了空间，并提供了寻找新的共同点的机会。该杂志邀请来自 STEAM、法律、哲学、社会和政治科学以及不同宗教神学等多个角度的投稿。该杂志定期发表有关脑死亡和出于良心拒绝医疗保健等长期存在的伦理问题的论文，同时重点关注新进展与人体的界面。它涵盖了基因组编辑、再生医学（包括干细胞的使用）、人类增强、体外发育和动物与人类杂交等问题。除了研究论文和书评之外，《新生物伦理学》还设有论文部分，与 7000 字以内的论文相比，作者有机会更深入地探讨问题。有关论文适用性的询问或讨论论文部分的潜在主题或特殊问题，可以发送电子邮件至 matthew.james@stmarys.ac.uk。同行评审政策 提交的论文被认为适合由主编进行同行评审，将在主编和总编辑的监督下，在杰出的国际顾问委员会的帮助下，接受独立审稿人的严格匿名评审。该杂志采用双匿名同行评审系统，每篇论文至少有两次评审。可以通过在线提交系统进行提交 www.edmgr.com/nbi 出版道德 本刊遵守出版道德的最高标准，并制定了严格的流程来确保这一目标的实现。 Taylor & Francis 是出版道德委员会 (COPE) 的成员，并对所有期刊使用 CrossCheck。有关我们道德标准和政策的更多信息，请访问：http://authorservices.taylorandfrancis.com/ethics-for-authors/ 《华尔街日报》有上诉和投诉政策，可在此处查看：https://authorservices.taylorandfrancis.com/peer-review-appeals-and-complaints-from-authors/。